Drug therapy of arrhythmia--ECG, a "cosmetic" or benefit to the patient?
Toivonen, L.; Heikkilä, J.
Duodecim; Laaketieteellinen Aikakauskirja 102(22): 1651-1661
1986
ISSN/ISBN: 0012-7183 PMID: 3803255 Document Number: 268599
Document emailed within 1 workday
Related Documents
Nakamura, H. 2004: Recent progress in molecular etiology of arrhythmia and anti-arrhythmia drug therapy Masui. Japanese Journal of Anesthesiology 53 Suppl: S81-S90Schollmeyer, P. 1973: Arrhythmia following drug therapy Die Medizinische Welt 24(26): 1092-1096
Nestor, M.S. 2004: Combination therapy in clinical and cosmetic dermatology: the marriage of device and drug Journal of Drugs in Dermatology: Jdd 3(5 Suppl): S4-11
Toivonen, L.; Heikkilä, J. 1987: Drug treatment of arrhythmias -- cosmetics of the ECG or benefit to the patient Annals of Clinical Research 19(1): 1-4
Gardner, J. 1999: Pharmacists join drug benefit debate. if Medicare offers prescription drug benefit, pharmacists want to be reimbursed Modern Healthcare 29(49): 6
Shinya, H.; Hakoda, S.; Kinouchi, S. 2006: Plasma drug levels in amitriptyline overdose patient with complicated delayed cardiac arrhythmia and convulsions Chudoku Kenkyu: Chudoku Kenkyukai Jun Kikanshi 19(3): 285-286
Sulimov, V.A. 1999: "Sicilian gambit": pathophysiological approach to drug therapy of arrhythmia (lecture] Terapevticheskii Arkhiv 71(8): 67-74
Bonhorst, D. 1992: Choice of anti-arrhythmia agents: the arrhythmia-patient binomial Revista Portuguesa de Cardiologia: Orgao Oficial da Sociedade Portuguesa de Cardiologia 11(4): 387-389
Chelariu-Raicu, A.; Coleman, R.L.; Sood, A.K. 2019: Anti-Angiogenesis Therapy in Ovarian Cancer: which Patient is it Most Likely to Benefit? Oncology 33(7)
Prochaczek, F.; Gałecka, J.; Becker, A. 1988: Use of non-invasive transdermal stimulation of the heart in selecting an anti-arrhythmia drug in a patient with supraventricular paroxysmal tachycardia with a re-entry mechanism within the atrioventricular node Kardiologia Polska 31(6): 337-342
Steinbeck, G. 1992: Which patient with sustained ventricular tachycardia is suited for long-term therapy with anti-arrhythmia drugs? Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 47(5): 195-201
Lerch, C. 1994: Responsibility for patient education in drug therapy from the viewpoint of the drug industry Zeitschrift für Arztliche Fortbildung 88(12): 1055-1060
Zimarino, M.; De Caterina, R. 2004: Glycoprotein IIb-IIIa antagonists in non-ST elevation acute coronary syndromes and percutaneous interventions: from pharmacology to individual patient's therapy: part 1: the evidence of benefit Journal of Cardiovascular Pharmacology 43(3): 325-332
Itani, Z.S. 1973: Henna: the cosmetic antimycotic drug Der Hautarzt; Zeitschrift für Dermatologie Venerologie und verwandte Gebiete 24(2): 83-85
Shekhtman, V.I. 1998: Ultracaine-new anesthetic drug in cosmetic surgery Khirurgiia 4: 56
1966: The Food, Drug and Cosmetic Act: amendments and regulations Bulletin of the New York Academy of Medicine 42(1): 65-78
Fallor, M.K. 1981: Drug therapy and the geriatric patient Delaware Medical Journal 53(5): 263-267
Joshi, P.P. 1999: Patient compliance with drug therapy Journal of the Association of Physicians of India 47(6): 655-656
Scotson, J.H. 1984: Patient opinion and drug therapy Practitioner 228(1393): 669-672
Pazdur, R. 2006: PROs: defining clinical benefit from the patient's perspective. Draft guidance provides direction in evaluating patient-reported outcomes Oncology 20(6): 660